Avoid common mistakes on your manuscript.
Author Correction: American Journal of Clinical Dermatology (2023) 24:837-847 https://doi.org/10.1007/s40257-023-00788-2
Page 840, Table 1 Baseline Patient Demographics and Clinical Characteristics
(ITT Population):
‘PPPASI score categories at randomization, n (%)’ section, ‘≤ 20’ row: The cell entry in the ‘Placebo’ column, which previously read:
“15 (34.1)”
should read:
"14 (31.8)”
‘PPPASI score categories at randomization, n (%)’ section, ‘≥ 21 to ≤ 30’ row: The cell entry in the ‘Placebo’ column, which previously read:
“18 (40.9)”
should read:
“19 (43.2)”
‘Focal infection status at randomization, n (%)’ section, ‘Presence’ row: The cell entry in the ‘Placebo’ column, which previously read:
“34 (77.3)”
should read:
“32 (72.7)”
‘Focal infection status at randomization, n (%)’ section, ‘Absence’ row: The cell entry in the ‘Placebo’ column, which previously read:
“10 (22.7)”
should read:
“12 (27.3)”
‘Focal infection status at randomization, n (%)’ section, 'Presence' row: The cell entry in the ‘Apremilast 30 mg BID’ column, which previously read:
“37 (80.4)”
should read:
“32 (69.6)”
‘Focal infection status at randomization, n (%)’ section, 'Absence' row: The cell entry in the ‘Apremilast 30 mg BID’ column, which previously read:
“9 (19.6)”
should read:
“14 (30.4)”
The corrected Table 1 is as follows:
Page 841, Fig. 1 legend:
The footnote that previously read:
“*Two-sided P-value (nominal) is based on chi-square test. Missing data were imputed by nonresponder imputation.”
should read:
“*Two-sided P-value is based on chi-square test. Missing data were imputed by nonresponder imputation.”
Page 841, Fig. 1:
The text above the PPPASI-50 columns that previously read:
“Treatment difference: 37.4% (95% CI: 18.6%, 56.1%) Nominal P=0.0003*”
should read:
“Treatment difference: 37.4% (95% CI: 18.6%, 56.1%) P=0.0003*”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Terui, T., Okubo, Y., Kobayashi, S. et al. Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study. Am J Clin Dermatol 25, 165–167 (2024). https://doi.org/10.1007/s40257-023-00825-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-023-00825-0